|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of metalloproteinase (MMP) 2 expression greatly contributed to the BRG1 induced increase in melanoma invasiveness.
|
20969766 |
2010 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, CA can be characterized as a novel V-ATPase inhibitor for the treatment of melanoma that may inhibit invasion and metastasis by downregulating the expression of MMP-2 and -9.
|
29113270 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Kinase activation led to increased MMP-2 and MT1-MMP expression and melanoma cell migration induced by hHK-1.
|
27458061 |
2016 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, alterations of SOCS-1 expression profoundly affected the expression of matrix metalloproteinase-2 (MMP-2), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) and the melanoma cell invasion and angiogenesis.
|
19047140 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.
|
9632718 |
1998 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings indicate that NCTD inhibits tumor growth and VM formation of melanoma both <i>in vitro</i> and <i>in vivo</i> by suppressing matrix metalloproteinase-2 expression.
|
28454306 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that METTL3 is upregulated in human melanoma and plays a role in invasion/migration through MMP2.
|
30762711 |
2019 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only 4 of the breast/colorectal 'hill' type CAN genes (SMAD4, MYO18B, NAV3 and MMP2) were also mutated in melanoma and pancreatic carcinoma, while none was altered in glioblastoma.
|
19058223 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma metastasis requires migration and invasion of the malignant tumour cells driven by proteolytic remodelling of the extracellular matrix (ECM) executed by matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9.
|
31020875 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In parallel to CD44v3, MMP-2 expression (determined using immunohistochemistry) was significantly elevated (P<0.05) but only in the organ metastatic group of MM.
|
11764382 |
2001 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also demonstrate that: (1) among the major pro-angiogenic genes, FGF-2 was not increased before or after irradiation and vascular endothelial growth factor strongly inhibited after irradiation; (2) expression of two important metalloproteinases, matrix metalloproteinase 2 and 9, involved in melanoma metastasis were decreased before and after irradiation; (3) expression of their major inhibitor, tissue inhibitor of metalloproteinase, was mainly upregulated; and (4) that invasion of BRCA1 downregulated cells was modified.
|
15009718 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that anterior lens capsule type IV collagen or specifically the synthetic peptide alpha3(IV) 185-203 inhibited both the migration of melanoma or fibrosarcoma cells as well as the activation of membrane-bound MMP-2 by decreasing the expressions of MT1-MMP and the beta3 integrin subunit.
|
10667602 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The caspase-3-mediated promotion of melanoma cell motility may be because of the cleavage of matrix metalloproteinase-2.
|
23695439 |
2013 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2.
|
12789289 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because MMP-2 activity is critical for melanoma progression, the MMP-2 peptide should be cross-presented by most progressing melanomas and represents a unique antigen for vaccine therapy of these tumors.
|
15998788 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.
|
30021673 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that of all tested components of the matrix metalloproteinase system, only expression of activated MMP-2 correlates with increased malignancy in our melanoma xenograft model, corroborating an important role of MMP-2 in human melanoma invasion and metastasis.
|
10555745 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, a long-term treatment (7 days) with these drugs markedly down-regulated the genes for both gelatinase A and B. Zymographic analysis showed that human melanoma primarily secretes the gelatinase-A activity, which showed changes similar to those seen in the corresponding mRNA after the treatments with interferons.
|
8056455 |
1994 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-33/ST2 Axis Regulates Vasculogenic Mimicry via ERK1/2-MMP-2/9 Pathway in Melanoma.
|
30928981 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Most melanoma cell lines and cultured normal melanocytes produced high levels of matrix metalloproteinase-2.
|
16718267 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.
|
16379022 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Interestingly, male patients with a melanoma with overexpression of MMP-2 showed a 10-year disease-specific survival of only 41% compared with 77% in other male patients (P = .003).
|
18187184 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Because MMP-2 activity is critical for melanoma progression, the MMP-2 peptide should be cross-presented by most progressing melanomas and represents a unique antigen for vaccine therapy of these tumors.
|
15998788 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.
|
11918086 |
2002 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Our pilot study demonstrates that MMP2, MMP14, MMP9, and MaxND might be used as prognostic markers in patients with sinonasal and oral malignant melanoma.
|
18045645 |
2008 |